Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Call Scheduled for Friday, November 3, 2017 at 10:30 a.m. ET
NEW YORK, Oct. 24, 2017 -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), will report financial results for the three- and nine-months ended September 30, 2017 and host a conference call and webcast at 10:30am Eastern Time on Friday, November 3.
Conference Call & Webcast
| Friday, November 3rd @ 10:30am Eastern Time | |
| Domestic: | 888-438-5449 |
| International: | 719-325-2450 |
| Passcode: | 1870535 |
| Webcast: | http://public.viavid.com/index.php?id=126768 |
| Replays available through November 17: | |
| Domestic: | 844-512-2921 |
| International: | 412-317-6671 |
| Conference ID: | 1870535 |
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
